Inventor · disambiguated record
Michael Hedvat
Also filed as: HEDVAT MICHAEL
17 granted patents·19 pending applications·89 citations·filing 2004–2025
92Inventor score
Top patents by PatentIndex Score
36 records- 0198US10793632B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2017·Granted Oct 6, 2020·22 cites·5 claims
- 0297US11591401B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Feb 28, 2023·19 cites·5 claims
- 0397US10787518B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2017·Granted Sep 29, 2020·15 cites·19 claims
- 0496US11919958B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Mar 5, 2024·9 cites·16 claims
- 0595US11919956B2Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3XENCOR INC·Filed 2021·Granted Mar 5, 2024·4 cites·8 claims
- 0695US10981992B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2018·Granted Apr 20, 2021·6 cites·6 claims
- 0794US11851466B2Targeted IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2020·Granted Dec 26, 2023·3 cites·16 claims
- 0893US11377477B2PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereofXENCOR INC·Filed 2019·Granted Jul 5, 2022·7 cites·13 claims
- 0991US11932675B2PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved propertiesGENENTECH INC·Filed 2020·Granted Mar 19, 2024·2 cites·15 claims
- 1085US2025333519A1Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2025·Application pending·0 cites
- 1184US12378326B2Anti-CD28 x anti-PSMA antibodiesXENCOR INC·Filed 2024·Granted Aug 5, 2025·0 cites·30 claims
- 1284US11236170B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2019·Granted Feb 1, 2022·1 cites·5 claims
- 1381US12404329B2Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3XENCOR INC·Filed 2024·Granted Sep 2, 2025·0 cites·6 claims
- 1481US2025388704A1Anti-cd28 x anti-psma antibodiesXENCOR INC·Filed 2025·Application pending·0 cites
- 1581US2023041377A1Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2022·Application pending·0 cites
- 1679US12365743B2Anti-CD28 x anti-PSMA antibodiesXENCOR INC·Filed 2023·Granted Jul 22, 2025·0 cites·1 claims
- 1779US11312770B2Bispecific and monospecific antibodies using novel anti-PD-1 sequencesXENCOR INC·Filed 2018·Granted Apr 26, 2022·1 cites·4 claims
- 1879US2024026002A1Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2023·Application pending·0 cites
- 1976US2023322961A1Anti-cd28 x anti-psma antibodiesXENCOR INC·Filed 2023·Application pending·0 cites
- 2075US2023257466A1Anti-cd28 compositionsXENCOR INC·Filed 2022·Application pending·0 cites
- 2173US11492407B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2019·Granted Nov 8, 2022·0 cites·6 claims
- 2273US2024279356A1Heterodimeric antibodies that bind msln and cd3XENCOR INC·Filed 2024·Application pending·0 cites
- 2373US2024294593A1Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved propertiesGENENTECH INC·Filed 2024·Application pending·0 cites
- 2469US12152076B2Bispecific and monospecific antibodies using novel anti-PD-1 sequencesXENCOR INC·Filed 2022·Granted Nov 26, 2024·0 cites·11 claims
- 2569US2021253706A1Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2021·Application pending·0 cites
- 2668US2023055445A1Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereofXENCOR INC·Filed 2022·Application pending·0 cites
- 2765US2023340128A1Anti-cd28 x anti-msln antibodiesXENCOR INC·Filed 2023·Application pending·0 cites
- 2865US2024059786A1Anti-cd28 x anti-trop2 antibodiesXENCOR INC·Filed 2023·Application pending·0 cites
- 2964US2023383012A1Antibodies that bind pd-l1, pd-l2, and/or cd28XENCOR INC·Filed 2023·Application pending·0 cites
- 3064US2025043001A1Anti-cd28 compositionsXENCOR INC·Filed 2024·Application pending·0 cites
- 3163US2025122299A1ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIESXENCOR INC·Filed 2024·Application pending·0 cites
- 3262US2022106403A1Heterodimeric antibodies that bind msln and cd3XENCOR INC·Filed 2021·Application pending·0 cites
- 3360US2021095030A1Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2020·Application pending·0 cites
- 3457US2022135684A1Bispecific antibodies that bind pd-l1 and cd28XENCOR INC·Filed 2021·Application pending·0 cites
- 3553US12006345B2Untargeted and targeted IL-10 Fc-fusion proteinsXENCOR INC·Filed 2020·Granted Jun 11, 2024·0 cites·13 claims
- 3646US2007104714A1Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axisCEDARS SINAI MEDICAL CENTER·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Hedvat files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →